Research
Hormonal
Hepatocellular carcinoma can develop in patients with nonalcoholic fatty liver disease (NAFLD) even in the absence of cirrhosis, often presenting with larger tumors and poorer prognosis due to lack of surveillance.
If you have fatty liver disease, be aware that liver cancer can develop even without advanced scarring (cirrhosis). Because these cases are often not detected early, it is important to discuss screening options with your doctor, especially if you have other metabolic risk factors like diabetes or obesity.
GoodSupportsMEDIUM confidence
a growing burden of evidence demonstrates that HCC can develop in individuals with NAFLD who do not have cirrhosis
Why this rating
Based on multiple cohort studies and case series, though exact burden is uncertain.
Source
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
Andrea Marengo et al. · Annual Review of Medicine · 2015
DOI 10.1146/annurev-med-090514-013832
narrative_reviewCited 790×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity and metabolic syndrome significantly increase the risk of hepatocellular carcinoma (HCC), with risk escalating as BMI increases and being further amplified by the presence of type 2 diabetes.Strong
- Metformin use is associated with a reduced incidence of hepatocellular carcinoma in patients with type 2 diabetes, whereas sulfonylurea or insulin use may increase risk.Good
- Statin use is associated with a reduced incidence of hepatocellular carcinoma in patients with NAFLD.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →